Activity

Silo Pharma Inc. (NASDAQ:SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved conditions. These conditions include stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases like Alzheimer’s and multiple sclerosis.
Here’s a summary of key information about Silo Pharma Inc. as of May 16 and 17, 2025:
Stock Information:
* Ticker Symbol: SILO (NASDAQ)
* Stock Price: Approximately $0.48 to $1.09 (fluctuating based on the source and time of data collection on May 16 and 17, 2025).
* Market Capitalization: Around $2.17 million to $4.8 million.
* 52-Week Range: $0.71 to $4.50.
Recent News and Developments:
* Public Offering: On May 16, 2025, Silo Pharma announced the closing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants) along with Series A-1 and Series A-2 warrants at a price of $0.60 per unit. This offering raised approximately $2 million in gross proceeds. The company intends to use these funds to further develop its biopharmaceutical therapeutics.
* Advancement of SPC-15 (PTSD Treatment):
* Silo Pharma selected Veloxity Labs in May 2025 for bioanalytical work supporting the Investigational New Drug (IND)-enabling Good Laboratory Practice (GLP) study for its intranasal PTSD therapy, SPC-15.
* The company also initiated a key safety study for SPC-15 with Frontage Laboratories in May 2025, moving it closer to a first-in-human trial. Silo Pharma anticipates beginning the FDA IND process for SPC-15 in 2025.
* SPC-15 is an intranasal serotonin 5-HT4 receptor agonist being developed for stress-induced psychiatric disorders like PTSD and anxiety. It potentially qualifies for the FDA’s streamlined 505(b)(2) regulatory pathway.
* Preclinical studies have shown promising results for SPC-15, including enhanced efficacy when combined with an NMDAR antagonist in animal models.
* SP-26 (Fibromyalgia and Chronic Pain): In April 2025, Silo Pharma announced that its SP-26 ketamine implant met all endpoints in a fibromyalgia study. SP-26 is a self-administered, non-opioid therapeutic. The company also initiated a pharmacokinetic and tolerability study for SP-26 in minipigs in early 2025.
* Other Pipeline Programs: Silo Pharma is also working on preclinical assets including SPC-14 (intranasal compound for Alzheimer’s disease) and SPU-16 (CNS-homing peptide targeting multiple sclerosis).
Research and Development Strategy:
* Silo Pharma focuses on licensing and funding research on therapeutics, including both traditional drugs and psychedelic formulations, which they believe can be transformative for patients.
* The company collaborates with leading universities and researchers.
* Silo Pharma is pursuing the 505(b)(2) regulatory pathway for some of its therapeutics, which they anticipate will lead to lower costs and a faster approval process.
Financial Information:
* Cash and Short-Term Investments (as of Sep 2024): $8.02 million.
* Total Assets (as of Sep 2024): $8.57 million.
* Net Income (for Fiscal Q3 2024): -$928,810.
Overall:
Silo Pharma is a development-stage company with a focus on innovative treatments for underserved conditions. Recent activities indicate progress in their lead programs, particularly SPC-15 for PTSD, as they move towards clinical trials. The recent public offering provides additional capital for these development efforts. However, as a development-stage biopharmaceutical company, it faces inherent risks associated with drug development, regulatory approvals, and market acceptance.

Video courtesy of Interactive Brokershome

Video courtesy of Interactive Brokers